Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
N-acetyltransferase 2 and CYP2E1 polymorphisms do not increase the risk of antituberculosis drug-induced hepatotoxicity in caucasian population Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008
Protective effect of N-acetylcysteine on anti tuberculosis drug-induced hepatotoxicity Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009
Incidence and timing of hepatotoxicity due to anti-tuberculous treatment Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Antituberculosis drug-induced hepatotoxicity: influence on the management and outcome of active tuberculosis (TB) Source: Annual Congress 2007 - Epidemiology of tuberculosis II Year: 2007
Antituberculosis drug- induced hepatitis, an unpredictable phenotype Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
The renal oxidative stress induced by tuberculostatic treatment correlated with nephrotoxic markers Source: Eur Respir J 2004; 24: Suppl. 48, 649s Year: 2004
Pharmacogenomics and drug-induced toxicity Source: Annual Congress 2009 - PG7 Drug-induced pulmonary toxicity Year: 2009
The nephrotoxic effect assesment of tuberculostatic drugs therapy by urinary enzymes Source: Eur Respir J 2004; 24: Suppl. 48, 654s Year: 2004
Hepatotoxicity due to antituberculosis drug treatment Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007
Retrial of identical agents in patients with toxic hepatitis caused by first line antituberculosis drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Cytochrome P450 pharmacogenetics: a possible predictor of pulmonary drug induced toxicity? Source: Eur Respir J 2007; 30: Suppl. 51, 488s Year: 2007
Experimental justification choise to prevent hepatotoxic reactions to anti-TB drugs based on gene-phenotypic characteristics Source: International Congress 2019 – Tuberculosis: diagnosis Year: 2019
Antituberculotic drug-induced medicamentous liver damages Source: Eur Respir J 2004; 24: Suppl. 48, 51s Year: 2004
Vestibular toxicity, an unusual side effect of isoniazid Source: Eur Respir J 2005; 26: Suppl. 49, 455s Year: 2005
Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Source: Eur Respir J 2007; 29: 347-351 Year: 2007
Efeect of substitution of pyrazinamid by ofloxacin in patients who developed drug induced hepatitis with anti-tuberculosis drugs on mortalty and re-hepatitis Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
The protective effects of ASA on free radical metabolism in cisplatin induced nephrotoxicity in experimental models Source: Eur Respir J 2003; 22: Suppl. 45, 528s Year: 2003
Efficacy of anti-tuberculosis therapy with INH, RIF and Bedaquiline in mice with different genetic susceptibility to the infection Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019